SOLICITATION NOTICE
68 -- Purchase 35 synthetically generated native and labeled peptides
- Notice Date
- 9/11/2012
- Notice Type
- Presolicitation
- NAICS
- 541711
— Research and Development in Biotechnology
- Contracting Office
- Department of Health and Human Services, Centers for Disease Control and Prevention, Procurement and Grants Office (Atlanta), 2920 Brandywine Road, Room 3000, Atlanta, Georgia, 30341-4146
- ZIP Code
- 30341-4146
- Solicitation Number
- 50201
- Archive Date
- 10/11/2012
- Point of Contact
- Vallerie M Redd, Phone: 770-488-2845
- E-Mail Address
-
gfj3@cdc.gov
(gfj3@cdc.gov)
- Small Business Set-Aside
- N/A
- Description
- The Centers for Disease Control and Prevention (CDC), National Center for Environmental Health (NCEH), intends to award a sole source contract to Midwest BioTech, P.O. Box 6150, Fishers, IN 46038 for the acquisition of 35 synthetically generated native and labeled peptides. The statutory authority for this sole source acquisition is 10 U.S.C 2304(c)(1) in accordance with FAR Part 6.302-1- only one responsible source and no other supplies or services will satisfy the agency requirement. The NAICS code for this procurement is 541711, Research and Development in Biotechnology. The period of performance for this procurement is 6 months. These peptides are used to analyze for the presence or absence of ricin in a clinical sample. These peptides are a critical part of our CLIA approved method to diagnose ricin intoxication, and in order to continue with our current CLIA approved method, we cannot make any changes in the method such as the source of the peptide synthesized to determine the presence or absence of ricin. The previous source of synthesis of this peptide substrate is Midwest Biotech, and in order to continue running our method under CLIA conditions, we must have the peptide synthesized from the same manufacturer. The requested peptide synthesis from Midwest Biotech is the only source for material which will allow us to continue running our method under CLIA conditions. Purchase of the peptide synthesis from another company would cause us to revalidate our CLIA method and would not allow us to report a diagnosis of ricin intoxication for many months. As a result of this synopsis, no competitive solicitation will be posted on FedBizOpps. We will issue only one solicitation to Midwest Biotech. However, all responsible sources that believe they can meet these requirements may submit their capabilities/qualifications statement to provide the services to Vallerie Redd via email ONLY at gfj3@cdc.gov with the solicitation number 50201 referenced in the subject line NO LATER THAN September 26, 2012. A determination by the Government not to compete this proposed action will be based on responses to this notice and are solely within the discretion of the Contracting Officer. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/CDCP/PGOA/50201/listing.html)
- Record
- SN02876489-W 20120913/120912000039-c8a5e6478e93a0996dc0db5f781be70c (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |